Amgen: Denosumab antibody enhances bone-mineral density

By Elaine Rigoli

Tampa, Fla., Sept. 19 - Amgen said results from a post-hoc exploratory analysis of an ongoing multi-center, phase 2 study showed that subjects treated with denosumab subcutaneously, 60 mg twice yearly for up to 24 months, experienced an improvement not only in bone mineral density but also in parameters of hip structural analysis, a technique that estimates geometric properties of bone strength.

In the study, patients were evaluated with dual energy X-ray absorptiometry, the recognized measure for bone mineral density. The scans were then analyzed with hip structural analysis software, providing an estimated measurement of bone geometry.

Specifically, denosumab therapy resulted in a 6.69% increase in the measure of cortical thickness at the femoral shaft; there was a 0.31% decrease, from baseline, in the placebo group.

In the open-label alendronate cohort, there was a 1.82 % increase in cortical thickness at the femoral shaft, the company noted in a news release.

Amgen is a Thousand Oaks, Calif., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.